Nephrogenic Systemic Fibrosis. Pathogenesis, Diagnosis, and Therapy

Journal of the American College of Cardiology

Volumn 53, Issue 18, 2009, Pages 1621-1628

  Kribben, Andreas ^a   Witzke, Oliver ^a   Hillen, Uwe ^a   Barkhausen, Jörg ^a   Daul, Anton E ^b   Erbel, Raimund ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b ELISABETH KRANKENHAUS ESSEN   (Germany)

Author keywords

gadolinium; magnetic resonance imaging; nephrogenic systemic fibrosis; renal failure

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMMUNOGLOBULIN; PENTOXIFYLLINE; SODIUM THIOSULFATE; THALIDOMIDE;

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG MEGADOSE; GLOMERULUS FILTRATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER DISEASE; MAGNETIC RESONANCE ANGIOGRAPHY; MORBIDITY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHYSIOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SKIN BIOPSY; THROMBOPHILIA; TREATMENT RESPONSE;

CONTRAST MEDIA; GADOLINIUM; GERMANY; HUMANS; KIDNEY FAILURE; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RISK FACTORS;

EID: 62349129232     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.12.061     Document Type: Review

References (73)

1. Cowper S.E., Robin H.S., Steinberg S.M., et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (2000) 1000-1001
2. Cowper S.E. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46 (2005) 763-765
3. The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR). http://www.icnfdr.org/ Accessed May 22, 2008
4. Kribben A. NSF-Register. http://www.nsf-register.de Accessed December 10, 2007
5. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
6. Marckmann P., Skov L., Rossen K., et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 (2007) 3174-3178
7. Endre Z.H. Nephrogenic systemic fibrosis: is any contrast safe in renal failure?. Intern Med J 37 (2007) 429-431
8. Cowper S.E., and Boyer P.J. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 8 (2006) 151-157
9. Marckmann P. Nephrogenic systemic fibrosis: epidemiology update. Curr Opin Nephrol Hypertens 17 (2008) 315-319
10. Deo A., Fogel M., and Cowper S.E. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2 (2007) 264-267
11. Rydahl C., Thomsen H.S., and Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 43 (2008) 141-144
12. Reilly R.F. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 3 (2008) 747-751
13. Todd D.J., Kagan A., Chibnik L.B., et al. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56 (2007) 3433-3441
14. Prince M.R., Zhang H., Morris M., et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248 (2008) 807-816
15. Wertman R., Altun E., Martin D.R., et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248 (2008) 799-806
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 Suppl 1 (2002) S1-S266
17. Boyd A.S., Zic J.A., and Abraham J.L. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56 (2007) 27-30
18. High W.A., Ayers R.A., Chandler J., et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 (2007) 21-26
19. Food and Drug Administration Public Alert. Information for health care professionals: gadolinium-based contrast agents for magnetic resonance imaging (marketed as magnevist, Multihance, Omniscan, OptiMARK, ProHance). http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htm Accessed August 5, 2007
20. European Agency for the Evaluation of Medicinal Products (EMEA). Public assessment report: increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents. http://www.ismrm.org/special/EMEA3.pdf Accessed May 28, 2008
21. Joffe P., Thomsen H.S., and Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5 (1998) 491-502
22. Swan S.K., Lambrecht L.J., Townsend R., et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 34 (1999) 443-448
23. Saitoh T., Hayasaka K., Tanaka Y., et al. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24 (2006) 445-451
24. Agarwal R., Brunelli S.M., Williams K., et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 24 (2009) 856-863
25. Thomsen H.S. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16 (2006) 2619-2621
26. Leiner T., Herborn C.U., and Goyen M. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 17 (2007) 1921-1923
27. Morcos S.K. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol 80 (2007) 73-76
28. Broome D.R., Girguis M.S., Baron P.W., et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188 (2007) 586-592
29. Khurana A., Runge V.M., Narayanan M., et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42 (2007) 139-145
30. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148-157
31. van der Molen A.J. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. J Med Imaging Radiat Oncol 52 (2008) 339-350
32. Othersen J.B., Maize J.C., Woolson R.F., et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22 (2007) 3179-3185
33. Swaminathan S., and Shah S.V. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18 (2007) 2636-2643
34. Robson L., and Hunter M. Volume-activated, gadolinium-sensitive whole-cell currents in single proximal cells of frog kidney. Pflugers Arch 429 (1994) 98-106
35. Idee J.M., Port M., Raynal I., et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20 (2006) 563-576
36. Cowper S.E., and Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 25 (2003) 358
37. Swaminathan S., Ahmed I., McCarthy J.T., et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145 (2006) 234-235
38. Ballen K. Targeting the stem cell niche: squeezing blood from bones. Bone Marrow Transplant 39 (2007) 655-660
39. Heeschen C., Aicher A., Lehmann R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (2003) 1340-1346
40. Knopp E.A., and Cowper S.E. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 21 (2008) 123-128
41. Cowper S.E., Rabach M., and Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66 (2008) 191-199
42. Cowper S.E. Nephrogenic systemic fibrosis: an overview. J Am Coll Radiol 5 (2008) 23-28
43. Mackay-Wiggan J.M., Cohen D.J., Hardy M.A., et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48 (2003) 55-60
44. Swartz R.D., Crofford L.J., Phan S.H., et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114 (2003) 563-572
45. Swaminathan S., High W.A., Ranville J., et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73 (2008) 1413-1418
46. Streams B.N., Liu V., Liegeois N., et al. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol 48 (2003) 42-47
47. Cowper S.E., Su L.D., Bhawan J., et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 (2001) 383-393
48. Kucher C., Xu X.W., Pasha T., et al. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 32 (2005) 484-490
49. Levine J.M., Taylor R.A., Elman L.B., et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 30 (2004) 569-577
50. Weiss A.S., Lucia M.S., and Teitelbaum I. A case of nephrogenic fibrosing dermopathy nephrogenic systemic fibrosis. Nat Clin Pract Nephrol 3 (2007) 111-115
51. Panesar M., Banerjee S., and Barone G.W. Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant 22 (2008) 803-808
52. Linfert D.R., Schell J.O., and Fine D.M. Treatment of nephrogenic systemic fibrosis: limited options but hope for the future. Semin Dial 21 (2008) 155-159
53. Artunc F., Schanz S., Metze D., et al. Nephrogenic systemic fibrosis. Dtsch Med Wochenschr 133 (2008) Suppl:F1
54. Jan F., Segal J.M., Dyer J., et al. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143 (2003) 678-681
55. Penfield J.G. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 23 (2008) 2121-2129
56. Leung N., Shaikh A., Cosio F.G., et al. The effect of kidney transplantation on nephrogenic systemic fibrosis. 41st Annual Meeting of the American Society of Nephrology (2008), American Society of Nephrology, Philadelphia, PA 441A
57. Pesek G.D., Tyler L., Theus J., et al. Extracorporal photopheresis (ECP), a promising treatment for nephrogenic fibrosing dermatopathy (NFD). J Am Soc Nephrol 17 (2006) 460A
58. Medicines and Healthcare products Regulatory Agency (online 7 February 2007) Public assessment report: increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&ssDocName=CON2030229&ssSourceNodeId=221&ssTargetNodeId=221 Accessed October 17, 2008
59. Penfield J.G., and Reilly R.F. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 3 (2007) 654-668
60. Kanal E., Barkovich A.J., Bell C., et al. ACR Guidance Document for Safe MR Practices: 2007. AJR Am J Roentgenol 188 (2007) 1447-1474
61. Segal A., Ellis J., Baumgartner B., et al. Manual On Contrast Media Version 6. http://www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx Accessed November 28, 2008
62. Michaely H.J., Thomsen H.S., Reiser M.F., and Schoenberg S.O. [Nephrogenic systemic fibrosis (NSF)-implications for radiology]. Radiologe 47 (2007) 785-793
63. Gebker R., Gomaa O., Schnackenburg B., et al. Comparison of different MRI techniques for the assessment of thoracic aortic pathology: 3D contrast enhanced MR angiography, turbo spin echo and balanced steady state free precession. Int J Cardiovasc Imag 23 (2007) 747-756
64. Pereles F.S., McCarthy R.M., Baskaran V., et al. Thoracic aortic dissection and aneurysm: evaluation with nonenhanced true FISP MR angiography in less than 4 minutes. Radiology 223 (2002) 270-274
65. Maki J.H., Wilson G.J., Eubank W.B., et al. Steady-state free precession MRA of the renal arteries: breath-hold and navigator-gated techniques vs. CE-MRA. J Magn Reson Imag 26 (2007) 966-973
66. Giorgi B., Dymarkowski S., Maes F., et al. Improved visualization of coronary arteries using a new three-dimensional submillimeter MR coronary angiography sequence with balanced gradients. AJR Am J Roentgenol 179 (2002) 901-910
67. Miyazaki M., Takai H., Sugiura S., et al. Peripheral MR angiography: separation of arteries from veins with flow-spoiled gradient pulses in electrocardiography-triggered three-dimensional half-Fourier fast spin-echo imaging. Radiology 227 (2003) 890-896
68. Dawson P., and Punwani S. Nephrogenic systemic fibrosis: non-gadolinium options for the imaging of CKD/ESRD patients. Semin Dial 21 (2008) 160-165
69. Feldkamp T., and Kribben A. Contrast media induced nephropathy: definition, incidence, outcome, pathophysiology, risk factors and prevention. Minerva Med 99 (2008) 177-196
70. Kane G.C., Stanson A.W., Kalnicka D., et al. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. Nephrol Dial Transplant 23 (2008) 1233-1240
71. Rosenkranz A.R., and Grobner T. Conventional or gadolinium containing contrast media: the choice between acute renal failure or nephrogenic systemic fibrosis?. Wien Klin Wochenschr 119 (2007) 271-275
72. Thomsen H.S., Marckmann P., and Logager V.B. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?. Acta Radiologica 48 (2007) 593-596
73. Rodby R.A. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial 21 (2008) 145-149